CompletedNot Applicable

Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)

China45 participantsStarted 2025-08-11

Plain-language summary

This is a retrospective, single-center study evaluating the effectiveness and safety of consolidative durvalumab after cCRT in LS-SCLC in real-world setting.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged ≥18 at initial diagnosis.
✓. Histologically or cytologically documented limited-stage SCLC (Stage I-III SCLC \[T any, N any, M0\] according to the American Joint Committee on Cancer Staging Manual \[AJCC Cancer Staging Manual, 9th Edition\] or the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology \[IASLC Staging Manual in Thoracic Oncology 2016\]).
✓. Received concurrent chemoradiotherapy (cCRT) as first-line treatment and consolidative durvalumab prior to disease progression or death:

Exclusion criteria

✕. Mixed SCLC and NSCLC histology.
✕. Participated in other interventional clinical trial for the treatment of any cancer during durvalumab therapy.

What they're measuring

rwPFS

Timeframe: Up to 60 months

Trial details

NCT IDNCT07050472

SponsorAnhui Shi, MD

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-08-12

View on ClinicalTrials.gov More Small-cell Lung Cancer trials